Cargando…

Clinical Characteristics of Omicron SARS-CoV-2 Variant Infection After Non-mRNA-Based Vaccination in China

INTRODUCTION: To date, little is known about the real-world protective role of Chinese inactivated and recombinant coronavirus disease 2019 (COVID-19) vaccines under the background of the long-term “Dynamic Zero COVID-19 Case” (i.e., no infection source) in China, especially when facing the widespre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zeng, Qing-Lei, Lv, Yuan-Jun, Liu, Xiao-Jing, Jiang, Zhi-Yong, Huang, Shuo, Li, Wei-Zhe, Yu, Zu-Jiang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Microbiology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9279136/ https://www.ncbi.nlm.nih.gov/pubmed/35847120 http://dx.doi.org/10.3389/fmicb.2022.901826

Ejemplares similares

Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants
por: Tseng, Hung Fu, et al.
Publicado: (2022)

Effects of vaccines on clinical characteristics of convalescent adult patients infected with SARS-CoV-2 Omicron variant: A retrospective study
por: Wang, Jingyu, et al.
Publicado: (2023)

Viable SARS-CoV-2 Omicron sub-variants isolated from autopsy tissues
por: Maffia-Bizzozero, Santiago, et al.
Publicado: (2023)

Importation of SARS-CoV-2 Omicron variant in Beijing, China
por: Li, Fu, et al.
Publicado: (2022)

Evaluation of the presence of SARS-CoV-2 in vaginal and anal swabs of women with omicron variants of SARS-CoV-2 infection
por: Liu, Ding, et al.
Publicado: (2022)

Rapid development of an updated mRNA vaccine against the SARS-CoV-2 Omicron variant
por: Zhang, Na-Na, et al.
Publicado: (2022)

SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination
por: Pajon, Rolando, et al.
Publicado: (2022)

Difference of Clinical Characteristics in Patients with Omicron and Delta Variants of SARS-CoV-2 in Beijing, China
por: Tian, Di, et al.
Publicado: (2023)

Elder and booster vaccination associates with decreased risk of serious clinical outcomes in comparison of Omicron and Delta variant: A meta-analysis of SARS-CoV-2 infection
por: Wu, Yanhua, et al.
Publicado: (2023)

SARS‐CoV‐2 Omicron variant: Characteristics and prevention
por: He, Xuemei, et al.
Publicado: (2021)

Author Correction: Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants
por: Tseng, Hung Fu, et al.
Publicado: (2022)

mRNA booster vaccination protects aged mice against the SARS-CoV-2 Omicron variant
por: Nanishi, Etsuro, et al.
Publicado: (2022)

Comparison of clinical characteristics between SARS-CoV-2 Omicron variant and Delta variant infections in China
por: Li, Qinggang, et al.
Publicado: (2022)

Tracking the first SARS-CoV-2 Omicron BA.5.1.3 outbreak in China
por: Wang, Xiaoxia, et al.
Publicado: (2023)

Performance of SARS-CoV-2 Antigen-Detecting Rapid Diagnostic Tests for Omicron and Other Variants of Concern
por: Raïch-Regué, Dàlia, et al.
Publicado: (2022)

A model simulation on the SARS-CoV-2 Omicron variant containment in Beijing, China
por: Liang, Shihao, et al.
Publicado: (2023)

Protection from successive Omicron variants with SARS-CoV-2 vaccine and monoclonal antibodies in kidney transplant recipients
por: Moal, Valérie, et al.
Publicado: (2023)

Clinical and upper airway characteristics of 3715 patients with the Omicron variant of SARS-Cov-2 in Changchun, China
por: Sha, Jichao, et al.
Publicado: (2023)

Heterologous mRNA vaccine booster increases neutralization of SARS-CoV-2 Omicron BA.2 variant
por: Li, Gen, et al.
Publicado: (2022)

SARS-CoV-2 mRNA Vaccine Elicits Sustained T Cell Responses Against the Omicron Variant in Adolescents
por: Choi, Sujin, et al.
Publicado: (2023)

Neutralizing Potency of Prototype and Omicron RBD mRNA Vaccines Against Omicron Variant
por: Zang, Jinkai, et al.
Publicado: (2022)

Booster of mRNA-1273 Strengthens SARS-CoV-2 Omicron Neutralization
por: Doria-Rose, Nicole A., et al.
Publicado: (2021)

COVID-19 mRNA booster vaccines elicit strong protection against SARS-CoV-2 Omicron variant in patients with cancer
por: Zeng, Cong, et al.
Publicado: (2022)

Why is the SARS-CoV-2 Omicron variant milder?
por: Xia, Bingqing, et al.
Publicado: (2022)

mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing activity against the SARS-CoV-2 omicron variant
por: Edara, Venkata-Viswanadh, et al.
Publicado: (2022)

mRNA Booster Vaccination Enhances Antibody Responses against SARS-CoV2 Omicron Variant in Individuals Primed with mRNA or Inactivated Virus Vaccines
por: Zhang, Biyan, et al.
Publicado: (2022)

Clinical characteristics of 310 SARS-CoV-2 Omicron variant patients and comparison with Delta and Beta variant patients in China
por: Yang, Wei, et al.
Publicado: (2022)

mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant
por: Gruell, Henning, et al.
Publicado: (2022)

Characteristic analysis of Omicron‐included SARS‐CoV‐2 variants of concern
por: Yang, Hao, et al.
Publicado: (2022)

Sub‐lineages of the SARS‐CoV‐2 Omicron variants: Characteristics and prevention
por: Xu, Ailan, et al.
Publicado: (2022)

Effectiveness of mRNA booster doses against the omicron variant
por: Zedan, Hadeel T, et al.
Publicado: (2022)

Clinical characteristics of liver injury in SARS-CoV-2 Omicron variant- and Omicron subvariant-infected patients
por: Deng, Haohui, et al.
Publicado: (2023)

A booster dose of Delta × Omicron hybrid mRNA vaccine produced broadly neutralizing antibody against Omicron and other SARS-CoV-2 variants
por: Lee, I-Jung, et al.
Publicado: (2022)

Broad-spectrum humanized monoclonal neutralizing antibody against SARS-CoV-2 variants, including the Omicron variant
por: Wen, Kun, et al.
Publicado: (2023)

Heterologous boost with mRNA vaccines against SARS-CoV-2 Delta/Omicron variants following an inactivated whole-virus vaccine
por: Lu, Changrui, et al.
Publicado: (2023)

Mapping Genetic Events of SARS-CoV-2 Variants
por: Qin, Luyao, et al.
Publicado: (2022)

Different pathogenesis of SARS-CoV-2 Omicron variant in wild-type laboratory mice and hamsters
por: Zhang, Ya-Nan, et al.
Publicado: (2022)

Clinical characteristics and analysis of risk factors for disease progression of patients with SARS-CoV-2 Omicron variant infection: A retrospective study of 25207 cases in a Fangcang hospital
por: Ying-hao, Pei, et al.
Publicado: (2022)

Neutralization of SARS-CoV-2 Omicron sublineages by 4 doses of mRNA vaccine
por: Xie, Xuping, et al.
Publicado: (2022)

mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant
por: Garcia-Beltran, Wilfredo F., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_bv1aqn1urrp4762usqgr3933sg